The US Federal Trade Commission has signaled that it would look more closely at biopharma acquisitions and might consider other factors than product overlap in determining their potential anticompetitive impact. But despite the greater scrutiny, the agency has cleared the sector’s big transactions over the past three years without imposing any divestiture requirements.
Pfizer Inc.’s proposed $43bn acquisition of Seagen Inc. is being closely watched as it is the largest biopharma deal since AbbVie Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?